BCL2L1 and cancer: We first questioned whether cancer cells treated with C75 showed increased sensitivity to BH3 mimetic drugs such as the dirty/promiscuous antagonist of BCL-2, BCL-XL, and BCL-W navitoclax/ABT-263 [49, 50].